Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2008
Business Overview: The company develops, manufactures, and markets oral specimen collection devices, diagnostic products (including in vitro diagnostic tests), and medical devices. Key products include the OraQuick ADVANCE HIV test, Intercept drug testing systems, and cryosurgical wart removal products. Sales are conducted in the U.S. and internationally to clinical laboratories, hospitals, government agencies, and distributors.
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenues | $18.1 million | $20.1 million |
| Gross Profit | $10.6 million | $12.5 million |
| Gross Margin | 59% | 62% |
| Operating Income (Loss) | $(3.0) million | $0.6 million |
| Net Income | $2.0 million | $1.5 million |
| Diluted EPS | $0.04 | $0.03 |
| Cash & Equivalents | $12.5 million | $16.8 million (End of Q1 2007) |
| Short-term Investments | $77.9 million | $63.3 million (Dec 31, 2007) |
| Total Liquidity (Cash + ST Inv) | $90.4 million | $95.6 million (Dec 31, 2007) |
| Long-term Debt | $8.7 million | $8.8 million (Dec 31, 2007) |
| Net Cash Used in Operating Activities | $(3.7) million | $(1.0) million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 10% to $18.1 million. This was driven by a 41% drop in cryosurgical systems revenue (due to the termination of the U.S. OTC distribution agreement with Prestige Brands) and a 17% decline in substance abuse testing revenue (impacted by economic conditions and reduced public sector funding).
- Product Mix Shift: Infectious disease testing revenue increased 6% to $9.5 million, primarily due to higher demand for the OraQuick ADVANCE HIV test in public health markets. Insurance risk assessment revenue surged 73% due to timing differences in distributor purchases.
- Operating Loss: The company reported an operating loss of $3.0 million compared to an operating income of $0.6 million in the prior year. This was caused by a 58% increase in R&D expenses (clinical trials for HIV OTC and HCV tests) and a 9% increase in sales and marketing expenses.
- Net Income Increase: Despite the operating loss, Net Income increased to $2.0 million (from $1.5 million) due to a $4.9 million one-time settlement payment from Schering-Plough recorded as "Other Income."
- Cash Flow: Operating cash flow usage increased to $3.7 million, primarily due to a $2.4 million increase in accounts receivable and a $0.9 million increase in inventories.
Guidance, Outlook, and Risks
- Outlook: Management expects R&D costs to increase in 2008 due to clinical trials for the OraQuick HIV OTC and HCV tests. Capital expenditures are expected to be $3.1 million for the remainder of the year. The company anticipates renewed growth in Intercept sales as employment conditions recover and customers shift from urine to oral fluid testing.
- Strategic Developments: The company is evaluating alternative strategies for OTC cryosurgical distribution in the U.S. and Canada following the termination of the Prestige agreement. A new collaboration with Schering-Plough for the HCV test was signed, though revenues are not expected to be material in 2008.
- Litigation Risk: On April 22, 2008, Inverness Medical Innovations and Church & Dwight filed a patent infringement lawsuit alleging the OraQuick ADVANCE HIV test infringes U.S. Patent No. 6,485,982. The company intends to defend vigorously, believing the patent is invalid or unenforceable.
- Supply Chain Risk: The company relies on sole-source providers for critical components (e.g., HIV-1 antigen). Disruptions or failure to obtain FDA approvals for alternative components could impact sales.
- Liquidity: The company maintains a $14 million credit facility with Comerica Bank. As of March 31, 2008, $9.3 million was outstanding on the facilities advance, and the company was in full compliance with all covenants.
Investor Verification Checklist
- One-Time Income Impact: Verify the sustainability of net income by excluding the $4.9 million Schering-Plough settlement, which masked an underlying operating loss.
- OTC Distribution Strategy: Monitor progress on securing a new distributor for the U.S. and Canadian OTC cryosurgical market to replace the terminated Prestige agreement.
- Patent Litigation: Track the status of the Inverness Medical/Church & Dwight lawsuit regarding the OraQuick HIV test, as an adverse ruling could impact a core revenue stream.
- R&D Burn Rate: Assess the timeline and cost of clinical trials for the OraQuick HIV OTC and HCV tests, which are driving significant expense increases.
- Accounts Receivable: Review the $2.4 million increase in receivables, noting that $1.5 million is attributable to two specific international distributors (SSL and Genomma).